TWD
OVID icon

True Wealth Design’s Ovid Therapeutics OVID Stock Holding History

True Wealth Design’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8
Closed -$3 – 2839
2025
Q2 		$3 Sell
8
-24
-75% -$7 ﹤0.01% 2562
2025
Q1 		$10 Buy
+32
New +$20 ﹤0.01% 2632

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

True Wealth Design's OVID Position: Q3 2025 in Review

True Wealth Design sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 8 shares — an estimated $3 sold.

True Wealth Design first reported a position in OVID in Q1 2025 and held it in 2 quarters. The position peaked at $10 in Q1 2025. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • True Wealth Design reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
  • True Wealth Design sold 8 Ovid Therapeutics shares in Q3 2025, an estimated $3.
  • True Wealth Design first reported a position in Ovid Therapeutics in Q1 2025 and held it in 2 quarters.
  • True Wealth Design's Ovid Therapeutics position peaked at $10 in Q1 2025.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.